NCT07155226View on ClinicalTrials.gov

Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

November 3, 2025

Primary Completion Date

June 18, 2029

Study Completion Date

June 18, 2029

Conditions
Acute Lymphoblastic LeukaemiaAcute Myeloid LeukaemiaHigher-risk Myelodysplastic Syndromes
Interventions
DRUG

AZD3632

AZD3632 will be administered orally.

DRUG

Posaconazole

Posaconazole will be administered orally.

Trial Locations (13)

40138

Research Site, Bologna

48121

Research Site, Ravenna

60590

Research Site, Frankfurt A. Main

62526

Research Site, Decatur

69120

Research Site, Heidelberg

77030

Research Site, Houston

81377

Research Site, München

89081

Research Site, Ulm

97239

Research Site, Portland

M5G 2M9

Research Site, Toronto

06097

Research Site, Halle

110-744

Research Site, Seoul

EH4 2XU

Research Site, Edinburgh

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY